Droia Oncology Ventures
VC
2011
$675 M
Zaventem, Flemish Brabant, Belgium
Profile
Droia Oncology Ventures is an investment firm specializing in life sciences, notably in oncology and genetic disease. Based in Belgium, Droia is led by a team of drug development experts and biotech professionals who actively support companies from creation through clinical proof of concept. What sets them apart is their hands-on approach, taking interim roles within portfolio companies to help them progress more swiftly.
The firm invests globally in young drug development companies with innovative approaches to address unmet medical needs. Droia targets sectors such as pharmaceuticals, biotechnology, and the broader life sciences space, focusing on companies capable of clinical breakthroughs. Their stage preference includes early-stage, Series A, and venture formation, with an investment range of $10-50 m. Specific fund sizes and strategic partners are not disclosed.
Notable investments by Droia include Accent Therapeutics - developing therapies in epitranscriptomics, Arcus Biosciences - focusing on immune-oncology combinations, and Frontier Medicines - leveraging chemoproteomics for drug development. Additional portfolio companies include Actio Biosciences, Alesta Therapeutics, Cyteir Therapeutics, and several others, indicating their broad reach within oncology and genetic disease therapeutics.
Industry
Droia Oncology Ventures Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Droia Oncology Ventures Fund II
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
HealthTech
|
Pre-seed
Seed
|
North America
Europe
|
$5-10 m
|
$265 M
|
May 2021
|
|
Fund II
|
Venture Capital (VC)
|
Healthcare Services
Marketing and Advertising
Media and Entertainment
SaaS
Software
HealthTech
|
Pre-seed
Seed
|
North America
Europe
|
$5-10 m
|
$62 M
|
April 2026
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.